Please upgrade your browser.
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting. Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations.
"They said, 'Will you sing?' So I said, 'Yes, because it's for a good cause and we want to raise awareness about kidney cancer.
Physicians should review a patient's CT imaging history and cumulative radiation dose when considering whether to perform another CT exam.
Tens of millions of Americans would lose their current health insurance and could also lose their current doctors, President Obama's reassurances notwithstanding. Since there aren't enough Americans earning more than $250,000 to finance the estimated $1.7 trillion price tag, reform would mean higher taxes for the middle class.
Favorable Response Rate in Patients Who Have Failed Prior Therapy.
Phase III clinical trial results show promise.
These results suggest that a targeted, antiangiogenic, oncolytic adenovirus might be a valuable agent for testing in kidney cancer patients.
If you have renal cell carcinoma and have received no prior systemic therapy (interleukin-2, interferon-alpha, chemotherapy, bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI), you may qualify for this study. Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=363.
What Republicans seemed to find even more infuriating was language allowing for the use of "reconciliation," a parliamentary procedure that would enable Democrats to enact health care legislation in the Senate with 51 votes, rather than the 60 necessary for overcoming a filibuster.
The award was presented on May 8, 2009 at the EU-KCA Symposium (Fourth European International Kidney Cancer Symposium, in Berlin, Germany.
|Powered by NeonCRM|